Lantern Pharma is an AI company that is transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern Pharma has accelerated the development of its growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, the company's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program. Lantern Pharma's lead development programs include two Phase 2 clinical programs and multiple upcoming Phase 1 clinical trials anticipated for 2023. The company has also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of its promising therapies for CNS and brain cancers, many of which have no effective treatment options. Lantern Pharma's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.